Drug manufacturers faced a variety of hurdles in 2024. Healthcare system reforms, preparation for the EU joint clinical assessments (JCAs) that went live at the
Since 2023, the pharmaceutical industry operating in Europe has faced an unprecedented challenge related to drug shortages. Previously, shortages were dictated by production capacity and
PD-1 inhibitors have become a paramount achievement in the oncology space and have revolutionised cancer treatment over the last decade. Their success is attributed to
In December 2023, Vertex (US) and CRISPR Therapeutics’s (Switzerland and US) Casgevy (exagamglogene autotemcel) was approved in the US for the treatment of sickle cell
Since the Russian invasion of Ukraine in early 2022, the Ukrainian budget has prioritised national security and defence. However, other significant priorities have been made
Share this article To gain insight into this landscape, the number of orphan drugs assessed by the G-BA, their innovation rating, and price impact compared
Share this article Takeda’s (Japan) Zejula (niraparib) was one of among six innovative anti-cancer medicines across 20 indications that were considered in this study. Credit:
Share this article According to POLI, the average time for HTA decisions in Germany and Italy is currently 317 and 557 days, respectively. Image: Arphaporn
The US is known for having higher list prices for drugs than other high-income countries. But these higher prices have not deterred investment and US
Subsequent HTA decisions have determined the advanced therapeutic treatment options available to patients under national health schemes. Credit: ART STOCK CREATIVE via Shutterstock. Health technology